Can You Have Great Insulin Sensitivity and Still Age Faster?

In longevity circles, one goal is taken for granted: keep your insulin sensitivity high. It is one of the cleanest signs of a metabolism in good order, and the quiet assumption is that a sharper insulin response also buys you more years. In 2026 a mouse study put that assumption in its title and pulled the two apart. Here is what the science actually says about insulin sensitivity and how long you live.

Where we stand. Good insulin sensitivity is a real sign of metabolic health, and we are not telling anyone to ignore it. The narrower claim we are checking is that raising insulin sensitivity, by itself, reliably extends human life. We grade that emerging, and leaning skeptical. The cleanest evidence that you can separate the two is in mice. The human data are associations that point in more than one direction. The lifestyle habits that improve insulin sensitivity are still worth doing, for reasons that go beyond a single number.

Why This Matters

Insulin sensitivity has quietly become one of the most chased numbers in the longevity world. People track it with continuous glucose monitors, fasting insulin tests, and HOMA-IR scores. The logic feels airtight. Insulin resistance sits underneath type 2 diabetes, heart disease, and a long list of age-related problems. So better insulin sensitivity should mean slower aging. Improve the number, improve your odds.

Most of that logic holds. Insulin resistance really is bad news, and reversing it really does lower your risk of several diseases. We have written about why metabolic health sits near the center of healthy aging, and none of that changes here.

What does change is the next step in the chain. There is a difference between "insulin sensitivity is a sign of a healthy body" and "insulin sensitivity is a lever you pull to live longer." The first is well supported. The second is where the science gets strange, because some of the most reliable ways to extend life in the lab involve turning insulin signaling down, and at least one careful study found animals with better insulin sensitivity dying sooner.

That gap, between a trustworthy health marker and an unreliable longevity lever, is the whole story. It is also a useful lesson in how to read any single-number health claim.

A Century of Treating Insulin as the Master Dial

The modern obsession starts with a real medical triumph. In 1921 and 1922, in a Toronto lab, Frederick Banting and Charles Best isolated insulin and turned type 1 diabetes from a death sentence into a treatable condition. Insulin became the master metabolic hormone in the public mind, the chemical that tells your cells to take up sugar and store energy.

Archival Photograph, 1922

Out of that history came a tidy mental model. Insulin sensitivity is how well your cells listen when insulin speaks. When they listen well, a small amount of insulin does the job, blood sugar stays low and steady, and the body runs clean. When they stop listening, that is insulin resistance, the body pumps out more and more insulin to compensate, and over years the wheels come off into prediabetes and diabetes.

So far, so good. The trouble is that this model quietly grew a second claim it was never built to support: that more insulin sensitivity is always better, all the way up, and that maximizing it is a path to a longer life. The biology of aging does not cooperate with that idea.

The Worm That Should Have Warned Us

The first crack in the story is more than thirty years old, and it is one of the most important results in the science of aging.

In 1993, Cynthia Kenyon and her colleagues reported that a single mutation in a gene called daf-2 made the worm C. elegans live roughly twice as long as normal (Kenyon and colleagues, Nature, 1993). The daf-2 gene turned out to be the worm's version of the receptor for insulin and IGF-1, the closely related growth hormone. In other words, the worms lived far longer because their insulin and IGF-1 signaling was turned down, not up.

This is the opposite of what the "more sensitivity is better" slogan would predict. Since then, the same basic finding has appeared again and again, in flies, in mice, and in the genetics of long-lived people. Reduced signaling through the insulin and IGF-1 pathway is one of the most reproducible levers for extending lifespan in the laboratory. Researchers gave it a name, the insulin/IGF-1 signaling pathway, and it became one of the central mechanisms of aging in the whole field.

Here is where people get confused, and the confusion is worth clearing up. Insulin resistance, the bad kind, is not the same as low insulin signaling, the longevity kind. Insulin resistance means your cells ignore insulin while the hormone piles up in your blood, so the tissue gets too much insulin pressure and too little benefit. The longevity pathway is about a body that runs on less insulin and IGF-1 overall, with cells that stay responsive. One is a traffic jam. The other is a quieter road. They can look superficially similar on a lab report and mean very different things.

That distinction is why some researchers have argued that the mild insulin resistance of old age might sometimes be a protective response rather than purely a disease, a way of dialing down growth signals when growth is no longer the priority (Barzilai and Ferrucci, Journals of Gerontology, 2012). That idea is still debated. But it tells you the simple slogan was never the whole truth.

What the Human Data Actually Shows

If lower insulin signaling extends life in animals, why do healthy long-lived humans tend to have good insulin sensitivity? Both things are true at once, and holding them together is the key to the whole topic.

On one side, exceptional human longevity does travel with good insulin action. In a classic study, healthy centenarians had better insulin sensitivity than typical adults in their seventies, closer to that of much younger people (Paolisso and colleagues, American Journal of Physiology, 1996). The children of people who live into their nineties also show better insulin sensitivity than their peers, which suggests something heritable is at work (Wijsman and colleagues, Aging Cell, 2011). So at the level of whole people, insulin sensitivity and long life clearly keep company.

On the other side, when you look at the genetics, the signal points toward dampened growth signaling. Researchers studying Ashkenazi Jewish centenarians found that mutations partially blunting the IGF-1 receptor were overrepresented, especially in long-lived women, a sign of reduced IGF-1 signaling rather than maximal signaling (Suh and colleagues, PNAS, 2008). The single most replicated longevity gene in humans, FOXO3, sits directly downstream of the insulin and IGF-1 pathway and was first linked to long life in long-lived Japanese-American men (Willcox and colleagues, PNAS, 2008), then confirmed in German centenarians (Flachsbart and colleagues, PNAS, 2009). Lower activity of this pathway has been associated with better survival in old age, again most clearly in women (van Heemst and colleagues, Aging Cell, 2005).

How do these fit together? The most reasonable synthesis is that good insulin sensitivity and modest growth signaling are both features of a body aging well, and they are not in conflict. A metabolism that stays insulin sensitive without running hot on insulin and IGF-1 is the pattern that travels with long life. That is a more careful claim than "max out your insulin sensitivity." It is closer to "keep the whole system balanced, and do not assume more of any one input is better."

Human caloric restriction makes the same point. In the CALERIE trial, the only randomized test of sustained calorie restriction in healthy adults, two years of eating about 12 percent less improved insulin sensitivity, with meaningful drops in fasting insulin and insulin resistance scores (Kraus and colleagues, Lancet Diabetes and Endocrinology, 2019). And separately, the same trial slowed a DNA-based measure of biological aging (Waziry and colleagues, Nature Aging, 2023). Here the two move together. The honest caveat is that calorie restriction changes dozens of things at once, so we cannot say the better insulin sensitivity is what slowed the aging clock. It might be a co-passenger, not the driver.

The 2026 Study That Named the Problem

In 2026, a study in Aging Cell stated the issue in its title: uncoupling insulin sensitivity from longevity (Lasher and colleagues, Aging Cell, 2026). It is the cleanest single demonstration that the two can be pried apart.

The researchers engineered mice without the receptor for glucagon in the liver. Glucagon is insulin's opposite number, the hormone that raises blood sugar, so removing its liver signal shifts the metabolic balance toward insulin's effects. These mice ended up leaner, with better glucose tolerance and enhanced insulin sensitivity. By every standard metabolic measure, they looked healthier.

And yet the female mice died sooner. Despite their better metabolic numbers, their lifespan was shorter, and the early deaths tracked with a rise in late-life inflammation in the liver and kidney, including activation of well known inflammatory pathways. The male mice, with the same genetic change and the same metabolic improvements, lived a normal span. Better insulin sensitivity, worse survival, and only in one sex.

It is one study, in mice, from a very specific genetic manipulation, and the sex split means we should be careful. But it is a clean existence proof. It shows that "more insulin sensitive" and "longer lived" are not welded together, and that you can improve one while quietly harming the other through a side door like inflammation.

It Is Not Just One Study

The 2026 paper did not come out of nowhere. A small run of recent work has been separating these two threads on purpose.

In 2025, researchers built a fruit fly with a mutated insulin receptor that, unusually, stayed fully insulin sensitive and normally grown, yet still lived longer than normal flies (Tatar and colleagues, PLoS Genetics, 2025). The extra lifespan came not from insulin resistance but from a reprogramming of methionine metabolism, an amino-acid pathway tied to longevity. The same group reported a parallel result in mice, where a similar mutation in the insulin or IGF-1 receptor produced features of long-lived animals while keeping their growth and glucose handling normal (Hernandez-Arciga and colleagues, JCI Insight, 2025). In both cases, the longevity and the metabolic health came apart and could be tuned somewhat independently.

The reverse experiment has also been done. When researchers improved insulin sensitivity in one set of mice by partially disabling insulin signaling only in peripheral tissues, the animals did not live any longer, and a more complete disruption actually shortened the males' lives (Merry and colleagues, Aging Cell, 2017). And in the famously long-lived growth-hormone-receptor knockout mouse, deliberately suppressing its unusually high insulin sensitivity stripped away some of its slow-aging features (Arum and colleagues, Aging Cell, 2014), which says insulin sensitivity is woven into that animal's longevity in a specific, conditional way rather than as a simple "more is better" dial.

To be fair to the other side, the coupling is sometimes real. In one well-known mouse study, lowering circulating insulin a modest amount both improved insulin sensitivity in old age and extended lifespan, the two moving in the same direction (Templeman and colleagues, Cell Reports, 2017). So this is not a story where insulin sensitivity is secretly bad. It is a story where the relationship is conditional. Sometimes they travel together, sometimes they split, and which one happens depends on how you got there.

When Forcing the Number Backfired

The strongest human warning against treating a metabolic number as a longevity dial does not come from insulin sensitivity directly. It comes from blood sugar, its close cousin.

In the ACCORD trial, doctors took people with type 2 diabetes and pushed their blood sugar down aggressively toward near-normal levels, the kind of tight control that looks ideal on paper. The intensive-treatment group had more deaths, not fewer, and the trial's intensive arm was stopped early for safety (ACCORD Study Group, New England Journal of Medicine, 2008). Longer follow-up confirmed the higher mortality (ACCORD Study Group, New England Journal of Medicine, 2011). Two other large trials of intensive glucose lowering, ADVANCE and VADT, did not show a survival benefit either. Driving a metabolic number toward "perfect" with drugs, in the wrong population, did harm.

IGF-1, the growth factor that shares the insulin pathway, tells a similar cautionary tale. Across large human studies, the relationship between IGF-1 levels and death risk is U-shaped: both low and high IGF-1 carry higher mortality, with the lowest risk somewhere in the middle (Rahmani and colleagues, Aging Cell, 2022). There is no "more is better" here, and no "less is better" either. There is a healthy middle.

None of this means good blood sugar or good insulin sensitivity are bad. It means the body is a system of trade-offs, and a single number taken to its extreme, especially by force, can move you off a healthy balance point without telling you.

So Should You Still Care About Insulin Sensitivity?

Yes, and here is the careful version of why.

Insulin sensitivity is a genuinely useful marker. Poor insulin sensitivity, the resistance that leads toward diabetes, is worth taking seriously and worth reversing. The everyday habits that improve it, regular movement and muscle-building exercise, not chronically overeating, decent sleep, and limiting ultra-processed food, are good for you through many channels at once, not just the insulin one. Nothing in the uncoupling research argues against any of that. If anything, it argues for it, because those habits improve the whole system rather than forcing one dial.

What the research argues against is treating insulin sensitivity as the single number that decides how long and how well you live, the one you push higher with supplements or aggressive drugs in the belief that a higher reading means more years. That leap is not supported. The animal biology often runs the other way. The human genetics point to balance, not maximum. And the one place we can force the related numbers with drugs in people, intensive glucose lowering, sometimes backfired.

This is also why the much-discussed idea of metformin for healthy people remains an open question rather than a settled one. Like rapamycin and other candidate longevity drugs, metformin improves metabolism in ways that look promising, and it shows intriguing survival signals in observational data (Bannister and colleagues, Diabetes, Obesity and Metabolism, 2014), which is why a dedicated trial, TAME, was designed to test whether it slows aging in non-diabetic older adults (Barzilai and colleagues, Cell Metabolism, 2016). The same caution applies to the GLP-1 drugs now reshaping metabolic medicine: improving a metabolic profile is not the same as proving an effect on human lifespan. As of 2026 that trial has not yet run, mostly for lack of funding. Until it does, "improves insulin sensitivity" is not the same as "extends human life," and it is worth keeping those two claims in separate boxes.

The practical mindset is the one we keep coming back to. Treat insulin sensitivity as a dashboard light, not the engine. When it is good, it tells you the metabolic system is in order, which is genuinely reassuring. When it is bad, it tells you something needs attention. But you do not make a car faster by taping the speedometer to a higher number, and you do not buy years of life by forcing a single metabolic reading to its extreme. You earn good insulin sensitivity as a byproduct of a body you have treated well, and that byproduct is a sign, not a promise.

Frequently Asked Questions

Is insulin resistance bad for healthy aging? Yes. Insulin resistance, where your cells stop responding well to insulin and the hormone builds up in your blood, sits underneath type 2 diabetes and raises the risk of heart disease and other age-related conditions. Improving it through exercise, weight management, and diet is worth doing. The nuance in this article is narrower: it is about whether pushing insulin sensitivity higher and higher, especially with drugs or supplements, reliably extends life. That second claim is the shaky one, not the basic value of avoiding insulin resistance.

If low insulin signaling extends life in animals, should I try to lower mine? No, not based on current evidence. The lifespan benefits of reduced insulin and IGF-1 signaling come from worms, flies, and mice with specific genetic changes, often present from birth. No human trial has shown that deliberately lowering insulin or IGF-1 signaling in healthy adults extends life, and the human data on IGF-1 suggest both too little and too much carry higher mortality. There is no safe, tested way for a person to copy the daf-2 worm, and good reasons to think the trade-offs differ in humans.

Does this mean my continuous glucose monitor or fasting insulin test is useless? Not useless, just easy to over-read. These tools give real information about your metabolic health, and a clearly poor result is worth acting on. The mistake is treating a single steady or improving number as proof you are aging more slowly. Biological aging is driven by many systems at once, and no one metabolic reading captures it. Use these tests as one signal among several, not as a longevity scoreboard.

Why did the 2026 mice with better insulin sensitivity die sooner? In that study, female mice were engineered without the liver receptor for glucagon, which improved their glucose control and insulin sensitivity. Despite looking metabolically healthier, they had shorter lifespans, and the early deaths went along with increased inflammation in the liver and kidney later in life. The effect appeared only in females; males with the same change lived normally. It is one mouse study with a very specific genetic manipulation, so the right takeaway is that insulin sensitivity and lifespan can come apart, not that insulin sensitivity is harmful.

What is the single most useful thing to do with all this? Keep doing the habits that improve insulin sensitivity, because they help your whole body, but stop treating insulin sensitivity as the number that decides how long you live. Build muscle, move daily, sleep well, and avoid chronic overeating. Let good insulin sensitivity be a result of those habits rather than a target you chase with pills. And be skeptical of any product or protocol that promises a longer life on the strength of one metabolic reading.

Sources

1. Kenyon C, Chang J, Gensch E, Rudner A, Tabtiang R. (1993). "A C. elegans mutant that lives twice as long as wild type." Nature, 366(6454), 461-464. PubMed: 8247153
2. Barzilai N, Ferrucci L. (2012). "Insulin resistance and aging: a cause or a protective response?" The Journals of Gerontology: Series A, 67(12), 1329-1331. PubMed: 22859390
3. Paolisso G, Gambardella A, Ammendola S, et al. (1996). "Glucose tolerance and insulin action in healthy centenarians." American Journal of Physiology, 270(5 Pt 1), E890-E894. PubMed: 8967479
4. Wijsman CA, Rozing MP, Streefland TC, et al. (2011). "Familial longevity is marked by enhanced insulin sensitivity." Aging Cell, 10(1), 114-121. PubMed: 21070591
5. Suh Y, Atzmon G, Cho MO, et al. (2008). "Functionally significant insulin-like growth factor I receptor mutations in centenarians." PNAS, 105(9), 3438-3442. PubMed: 18316725
6. Willcox BJ, Donlon TA, He Q, et al. (2008). "FOXO3A genotype is strongly associated with human longevity." PNAS, 105(37), 13987-13992. PubMed: 18765803
7. Flachsbart F, Caliebe A, Kleindorp R, et al. (2009). "Association of FOXO3A variation with human longevity confirmed in German centenarians." PNAS, 106(8), 2700-2705. PubMed: 19196970
8. van Heemst D, Beekman M, Mooijaart SP, et al. (2005). "Reduced insulin/IGF-1 signalling and human longevity." Aging Cell, 4(2), 79-85. PubMed: 15771611
9. Kraus WE, Bhapkar M, Huffman KM, et al. (2019). "2 years of calorie restriction and cardiometabolic risk (CALERIE): exploratory outcomes of a multicentre, phase 2, randomised controlled trial." The Lancet Diabetes and Endocrinology, 7(9), 673-683. PubMed: 31303390
10. Waziry R, Ryan CP, Corcoran DL, et al. (2023). "Effect of long-term caloric restriction on DNA methylation measures of biological aging in healthy adults from the CALERIE trial." Nature Aging, 3(3), 248-257. PubMed: 37118425
11. Lasher AT, Heckman B, Sarker P, Liu K, Sun LY. (2026). "Uncoupling insulin sensitivity from longevity: a sex-dependent effect of hepatic glucagon signaling." Aging Cell, 25(1), e70349. PubMed: 41482628
12. Tatar M, Zheng W, Yadav S, et al. (2025). "An insulin-sensitive Drosophila insulin-like receptor mutant remodels methionine metabolism to extend lifespan." PLoS Genetics, 21(6), e1011640. PubMed: 40523036
13. Hernandez-Arciga U, Kim JK, Fisher JL, et al. (2025). "Mutation in IR or IGF1R produces features of long-lived mice while maintaining metabolic health." JCI Insight. PubMed: 41217825
14. Merry TL, Kuhlow D, Laube B, et al. (2017). "Impairment of insulin signalling in peripheral tissue fails to extend murine lifespan." Aging Cell, 16(4), 761-772. PubMed: 28544360
15. Arum O, Boparai RK, Saleh JK, et al. (2014). "Specific suppression of insulin sensitivity in growth hormone receptor gene-disrupted (GHR-KO) mice attenuates phenotypic features of slow aging." Aging Cell, 13(6), 981-1000. PubMed: 25244225
16. Templeman NM, Flibotte S, Chik JHL, et al. (2017). "Reduced circulating insulin enhances insulin sensitivity in old mice and extends lifespan." Cell Reports, 20(2), 451-463. PubMed: 28700945
17. ACCORD Study Group. (2008). "Effects of intensive glucose lowering in type 2 diabetes." New England Journal of Medicine, 358(24), 2545-2559. PubMed: 18539917
18. ACCORD Study Group. (2011). "Long-term effects of intensive glucose lowering on cardiovascular outcomes." New England Journal of Medicine, 364(9), 818-828. PubMed: 21366473
19. Rahmani J, Montesanto A, Giovannucci E, et al. (2022). "Association between IGF-1 levels ranges and all-cause mortality: a meta-analysis." Aging Cell, 21(2), e13540. PubMed: 35048526
20. Bannister CA, Holden SE, Jenkins-Jones S, et al. (2014). "Can people with type 2 diabetes live longer than those without? A comparison of mortality in people initiated with metformin or sulphonylurea monotherapy and matched, non-diabetic controls." Diabetes, Obesity and Metabolism, 16(11), 1165-1173. PubMed: 25041462
21. Barzilai N, Crandall JP, Kritchevsky SB, Espeland MA. (2016). "Metformin as a tool to target aging." Cell Metabolism, 23(6), 1060-1065. PubMed: 27304507

Funding Transparency

LSD is editorially independent. We receive no funding from pharmaceutical, supplement, or longevity companies. In the interest of full transparency, here are the funding and conflict relationships behind the research cited above:

• Sources #1, #11, #12, #13, #14, #16 (the core animal lifespan studies): These worm, fly, and mouse studies were funded largely by public and academic sources, including the US National Institutes of Health and the National Institute on Aging, along with university programs. None carries a supplement-industry stake in the result.
• Sources #5, #6, #7, #8, #21 (the human longevity genetics and the metformin framing): Much of this work traces to academic centers such as the Albert Einstein College of Medicine's longevity research and public funders. Source #21 lays out the rationale for the TAME trial; its authors are longevity researchers with academic and nonprofit affiliations, and metformin is a generic drug with no commercial sponsor behind the trial.
• Sources #9, #10 (the CALERIE caloric restriction trial): Funded by the US National Institute on Aging, a public source. No commercial diet or supplement company stands behind the design or the result.
• Sources #17, #18 (the ACCORD trial): Funded by the US National Heart, Lung, and Blood Institute, with study drugs and some materials supplied by manufacturers, which is routine for a large diabetes trial. The headline finding, that intensive glucose lowering increased deaths, runs against any commercial interest in selling more aggressive treatment, which strengthens rather than weakens its credibility.
• Source #20 (the metformin survival signal): An observational analysis using a UK clinical database. It is a signal, not proof, and observational comparisons like this are vulnerable to hidden differences between groups, so we present it as a reason to run a trial, not as evidence that metformin extends life.
• General note: Several of the human findings are associations, not experiments. We have flagged that in the text. Associations can show what travels with long life without proving cause, which is the central reason this whole topic is graded emerging rather than settled.

Related Reading

• Metabolic Health Fundamentals - The bigger picture of how your body handles fuel, and where insulin sensitivity fits among the markers worth watching.
• Caloric Restriction and Fasting - The intervention that improved insulin sensitivity and slowed a measure of aging in the same human trial, and what that does and does not prove.
• Healthspan vs Lifespan - Why living longer and living well are different goals, and why a single metabolic number rarely settles either one.
• The Hallmarks of Aging - The full set of mechanisms that drive aging, of which deregulated nutrient sensing, the insulin and IGF-1 pathway, is only one.
• Your Body's Biomarkers - How blood markers become signals of biological age, and why no single reading deserves to be treated as a verdict.

This article is for education, not medical advice. It does not argue against managing insulin resistance or diabetes, which you should take seriously. Talk to your doctor before changing how you manage blood sugar, and before starting any drug or supplement aimed at metabolism or aging.

Written with the help of AI tools, shaped and verified by humans who care about getting this right.